logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Pulmonary Arterial Hypertension

    FiltersReset Filters
    21 results

    • adcirca

      (Tadalafil)
      United Therapeutics Corporation
      Usage: ADCIRCA® is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise capacity. It has been primarily studied in patients with NYHA Functional Class II-III symptoms, including cases of idiopathic or heritable PAH and PAH linked to connective tissue diseases.

    • alyq

      (Tadalafil)
      Teva Pharmaceuticals Inc
      Usage: ALYQ® (tadalafil tablets) is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in patients, particularly those with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH tied to connective tissue diseases.

    • ambrisentan

      (ambrisentan)
      Sun Pharmaceutical Industries, Inc.
      Usage: Ambrisentan is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening, primarily in patients with WHO Functional Class II–III symptoms and idiopathic, heritable, or connective tissue disease-associated PAH.

    • bosentan

      (bosentan)
      Actavis Pharma, Inc.
      Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults and pediatric patients aged 3 and older. In adults, it improves exercise ability and decreases clinical worsening, while in children, it aims to improve pulmonary vascular resistance, enhancing exercise performance.

    • bosentan

      (Bosentan)
      Amneal Pharmaceuticals LLC
      Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults. They improve exercise ability and reduce clinical worsening in patients with WHO Functional Class II-IV symptoms due to idiopathic or heritable PAH, connective tissue diseases, or congenital heart disease with left-to-right shunts.

    • bosentan

      (Bosentan)
      Zydus Pharmaceuticals USA Inc.
      Usage: Bosentan tablets are indicated for treating pulmonary arterial hypertension (PAH) in adults. They improve exercise ability and reduce clinical worsening, particularly in patients with WHO Functional Class II-IV symptoms related to idiopathic or heritable PAH, connective tissue diseases, and congenital heart disease with left-to-right shunts.

    • epoprostenol

      (EPOPROSTENOL)
      Mylan Institutional LLC
      Usage: Epoprostenol for injection is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity, primarily in patients with NYHA Functional Class III-IV symptoms, including those with idiopathic, heritable PAH, or PAH associated with connective tissue diseases.

    • letairis

      (AMBRISENTAN)
      Gilead Sciences, Inc
      Usage: Letairis is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise capacity, delay clinical worsening, and reduce disease progression and hospitalization risks when combined with tadalafil. It is primarily studied in patients with WHO Functional Class II–III symptoms related to idiopathic, heritable PAH, or connective tissue diseases.

    • opsumit

      (macitentan)
      Actelion Pharmaceuticals US, Inc.
      Usage: OPSUMIT is indicated for treating pulmonary arterial hypertension (PAH, WHO Group I) to reduce disease progression and hospitalization risks. Its effectiveness was demonstrated in a long-term study involving patients with various forms of PAH, primarily those with WHO Functional Class II–III symptoms.

    • orenitram

      (treprostinil)
      United Therapeutics Corporation
      Usage: Orenitram is indicated for treating pulmonary arterial hypertension (PAH) to delay disease progression and improve exercise capacity, primarily in patients with WHO functional class II-III symptoms, including idiopathic, heritable, or connective tissue disease-associated PAH.